Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
| ophthalmologic_monitoring_management_raf_mek_pathway_inhibitors [2026/07/01 22:34] – [Dose Modification Framework] Scott Larson | ophthalmologic_monitoring_management_raf_mek_pathway_inhibitors [2026/07/01 22:38] (current) – [Ophthalmologic Monitoring and Management for RAF/MEK Pathway Inhibitors] Scott Larson | ||
|---|---|---|---|
| Line 1: | Line 1: | ||
| ====== Ophthalmologic Monitoring and Management for RAF/MEK Pathway Inhibitors ====== | ====== Ophthalmologic Monitoring and Management for RAF/MEK Pathway Inhibitors ====== | ||
| - | Here is a comprehensive overview of recommended ophthalmologic monitoring protocols and management strategies for patients on RAF/MEK pathway inhibitors, applicable to tovorafenib and its drug class. | + | Here is a comprehensive overview of recommended ophthalmologic monitoring protocols and management strategies for patients on [[mapk_pathway_drugs_ocular_toxicity|RAF/MEK pathway inhibitors]], applicable to tovorafenib and its drug class. |
| ===== Baseline Ophthalmologic Assessment ===== | ===== Baseline Ophthalmologic Assessment ===== | ||
| Line 78: | Line 78: | ||
| - Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular Adverse Events Associated With MEK Inhibitors. //Retina//. 2019; | - Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular Adverse Events Associated With MEK Inhibitors. //Retina//. 2019; | ||
| - Urner-Bloch U, Urner M, Jaberg-Bentele N, et al. MEK Inhibitor-Associated Retinopathy (MEKAR) in Metastatic Melanoma: Long-Term Ophthalmic Effects. //Eur J Cancer//. 2016; | - Urner-Bloch U, Urner M, Jaberg-Bentele N, et al. MEK Inhibitor-Associated Retinopathy (MEKAR) in Metastatic Melanoma: Long-Term Ophthalmic Effects. //Eur J Cancer//. 2016; | ||
| + | |||
| + | {{tag> | ||